Roivant Insider Pulik Files Form 4; No Transaction Details

TL;DR

**Roivant insider filed a Form 4, but it's just a placeholder, no actual trades reported.**

AI Summary

Richard Pulik, a reporting insider for Roivant Sciences Ltd., filed a Form 4 on March 24, 2026, indicating a change in beneficial ownership of securities. While the filing details the reporting person and the issuer, it does not specify any transactions (buys or sells) or the number of shares involved. This matters to investors because Form 4 filings disclose insider trading activity, which can signal management's confidence (or lack thereof) in the company's future, but in this case, no specific transaction details are provided.

Why It Matters

This filing indicates an insider at Roivant Sciences Ltd. has a change in beneficial ownership, but without transaction details, it provides no actionable insight into their view of the company's stock.

Risk Assessment

Risk Level: low — The filing itself is administrative and does not report any specific transactions that would indicate a change in company fundamentals or insider sentiment.

Analyst Insight

Investors should note that while an insider filed a Form 4, the absence of transaction details means there's no immediate actionable information regarding insider buying or selling activity. Further investigation into subsequent filings or company disclosures would be needed for more insight.

Key Players & Entities

• Pulik Richard (person) — Reporting Person
• Roivant Sciences Ltd. (company) — Issuer
• 0001885841 (person) — CIK of Pulik Richard
• 0001635088 (company) — CIK of Roivant Sciences Ltd.

FAQ

Filing Documents

• wk-form4_1774393730.html (4)
• wk-form4_1774393730.xml (4) — 4KB
• 0001635088-26-000030.txt ( ) — 5KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Pulik Richard (Last) (First) (Middle) C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY (Street) LONDON SW1H 0DB (City) (State) (Zip) UNITED KINGDOM (Country) 2. Issuer Name and Ticker or Trading Symbol Roivant Sciences Ltd. [ ROIV ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) CFO 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 03/20/2026 F 1,546 (1) D $ 27.7 236,867 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Remarks: By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR